Samsung Biologics’ Mergers and Acquisitions: A New Era for Korea’s Biopharma Industry
Samsung Biologics, a leading South Korean biopharmaceutical company, has recently made significant moves in the mergers and acquisitions (M&A) space, reshaping both its corporate structure and the broader industry landscape. Full Acquisition of Samsung Bioepis In April 2022, Samsung Biologics completed the full acquisition of Samsung Bioepis by purchasing Biogen’s stake in their joint venture for $2.3 billion. This transaction transformed Samsung Bioepis into a wholly owned subsidiary of Samsung Biologics, granting the company greater autonomy and agility in its operations. The acquisition was strategically funded through a capital increase, with the expectation of accelerating growth in biosimilars and novel therapeutics R&D. According to John Rim, CEO of Samsung Biologics, this milestone would help the company leverage its contract development and manufacturing expertise to drive further innovation and address a wider range of diseases. Strategic Spin-Off and Corporat...